Omeros is a Seattle biotechnology company that develops drugs targeting the complement system, including its approved treatment YARTEMLEA. It last closed at $13.92 on Nov 17, down 16.55% on the day. OMER last reported earnings on Mon, Nov 16, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in OMER, 100% of them bullish and 0% bearish.
Only 1 firm rated OMER in the past 90 days, not enough for a consensus
Average 12-month target
$22.00
▲ 58.0% upside
Based on 1 analyst who set a price target on OMER in the past 90 days. The average target is $22.00, with a high of $22.00 and a low of $22.00, compared with the last close of $13.92.
Highest target$22.00
Average target$22.00
Lowest target$22.00
Latest rating changes
Cantor FitzgeraldReiterated
Oct 14Buy$22
Cantor FitzgeraldUpgrade
Sep 22Buy$22
HC Wainwright & Co.Maintained
Jun 26Buy$33
Date
Firm
Action
Rating
Price target
Oct 14
Cantor Fitzgerald
Reiterated
Buy
$22
Sep 22
Cantor Fitzgerald
Upgrade
Buy
$22
Jun 26
HC Wainwright & Co.
Maintained
Buy
$33
Loading…
Technical Analysis
OMER · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold
The stock is 24% below its 20 day and 30% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 31), oversold. The nearest support is the Pivot at $13.91, and the nearest resistance the Pivot R1 at $15.11.
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 7.9%/day
Key levels
$21.2452 week high+52.6%
$18.14Swing high (Aug 13)+30.3%
$18.1250 day average+30.2%
$17.3020 day average+24.3%
$15.91100 day average+14.3%
$15.11Pivot R1+8.5%
$13.92Last close
$13.91Pivot−0.1%
$13.80200 day average−0.9%
$12.72Pivot S1−8.6%
$10.55Swing low (May 27)−24.2%
$6.7052 week low−51.9%
Indicators
RSI (14)
30.76
Weak, oversold below 30
Neutral
MACD
-0.45
Below its signal line
Bearish
Stochastic
20.6
Middle of its range
Neutral
ADX (14)
14.5
No clear trend
Williams %R
-81.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-305.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.8%
Change over 10 sessions
Bearish
ATR (14)
$1.10
Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 16.8%/day
Key levels
$21.2452 week high+52.6%
$18.14Swing high (Aug 13)+30.3%
$18.1250 day average+30.2%
$17.3020 day average+24.3%
$15.91100 day average+14.3%
$15.11Pivot R1+8.5%
$13.92Last close
$13.91Pivot−0.1%
$13.80200 day average−0.9%
$12.72Pivot S1−8.6%
$10.55Swing low (May 27)−24.2%
$6.7052 week low−51.9%
Indicators
RSI (14)
46.20
Middle of its range
Neutral
MACD
1.23
Below its signal line
Bearish
Stochastic
40.8
Middle of its range
Neutral
ADX (14)
25.1
Trending down
Williams %R
-85.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-33.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−23.9%
Change over 10 sessions
Bearish
ATR (14)
$2.34
Typical daily range, 16.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for OMER
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OMER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OMER usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OMER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OMER is in one of them and how their past OMER trades turned out.
Omeros is a biotechnology company based in Seattle, Washington, that develops drugs aimed at the complement system, a part of the body's immune system. Its approved product, YARTEMLEA, treats thrombotic microangiopathy, a serious complication that can follow stem cell transplants, and it is sold for use in the United States. The company is also developing treatments for other immune conditions and for addiction. Its customers are patients and the hospitals and doctors who treat them.